FDA reviewed a bundle based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 system style and NDA requirements. Richard King, AcelRx CEO stated, ‘Given this guidance, we’ve clarity on the development path for ARX-02 in cancer breakthrough discomfort. Furthermore, FDA provided clarity on the advancement requirements to join up ARX-02 for the broader indication of chronic breakthrough discomfort in opioid-tolerant patients, where we think that ARX-02 can have an impact on the entire lives of a broader array of opioid-tolerant patients.’.. AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for malignancy breakthrough pain management system AcelRx Pharmaceuticals, Inc.To learn more, visit About Decision Assets, Inc. Decision Assets, Inc. Is usually a cohesive portfolio of companies that offers best-in-class, high-value info and insights on important sectors of the healthcare industry. Clients depend on this evaluation and data to make informed decisions. Please visit Decision Assets, Inc. At.. Achillion reviews lower net loss of $5.6M for first-quarter 2010 Achillion Pharmaceuticals, Inc. , a innovator in the discovery and development of small molecule drugs to combat the most demanding infectious diseases, today reported financial outcomes for the 90 days ended March 31, 2010.